TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients 18 years old or older~* patients who signed informed consent~* patients with dilated cardiomyopathy (according ESC 2007)~* patients who had no significant coronary artery stenoses \>30% on cardiac catheterization~Exclusion Criteria:~* BP ≥140/90 lub \<90/60~* congenital heart disease~* acquired valvular disease except for mitral incompetence secondary to left ventricular dilatation~* New York Heart Association (NYHA) functional class IV~* statin treatment~* preserved hyperactivity of aminotransferases with unexplained etiology,~* muscle disorders which might cause drug-induced myopathy,~* uncontrolled diabetes,~* liver diseases,~* creatinine level \> 2 mg/dl and/or GFR\<30ml/min,~* abuse of alcohol or drugs,~* chronic inflammatory diseases,~* pregnancy or lactation,~* severe hypothyroidism,~* immunosuppressive treatment,~* operation or severe injury during last month~* vaccination during last 3 months~* heart stimulation device or implantable cardioverter defibrillator~* or who didn't write conscious consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: None): None
- No statin (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alpha Lipoic Acid for Treatment of Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetic patients (according to American Diabetes Association (ADA) criteria)~* Symptomatic diabetic polyneuropathy~* Total Symptom Score (TSS) \>7 points,~* HbA1c\<10%,~* Serum creatinine \<2 mg/dl.~Exclusion Criteria:~* Active cardiovascular disease~* Malignancy~* Any other conditions causing neuropathic pain~* Use of analgesic, antidepressant, or antiepileptic drugs, or any other medication aimed to relief neuropathic pain.~* Child-bearing female patients not using any effective birth control method and under surveillance of a board-certified gynecologist

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- alpha lipoic acid treatment (Type: ACTIVE_COMPARATOR): After a decrease in the total symptoms score \>3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks 600 mg orally once a day of alpha lipoic acid
- alpha lipoic acid withdrawal (Type: NO_INTERVENTION): After a decrease in the total symptoms Score \>3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks no treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand English~* For the past 12 months, has smoked 5 or more cigarettes a day~* 18 years or older~* Planning on Quitting smoking someday~* Access to a telephone~* Willing and able to use NRT in the form of gum~* Not currently using chantix or wellbutrin~Exclusion Criteria:~* Planning to quit smoking cigarettes in the next 30 days~* Currently pregnant, breastfeeding, or planning to become pregnant in the next 12 months~* Currently using chantix or wellbutrin~* Diagnosed with an unstable heart condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Brief Advice (Type: PLACEBO_COMPARATOR): Participants will receive brief advice to quit smoking, and be provided psycho-education citing health consequences and the positive impact on mortality and morbidity.
- Motivational Interviewing (MI) (Type: EXPERIMENTAL): Motivational interviewing (MI) is a collaborative conversation style for strengthening a person's own motivation and commitment to change. MI attempts to avoid a confrontational style and, instead, guides participants toward choosing to make a change in their behavior.
- Rate Reduction (RR) (Type: EXPERIMENTAL): Participants will be informed of the strong medical evidence of systematic reductions in smoking behavior can lead to long-term smoking cessation. This condition will receive Nicotine Replacement Therapy in the form of gum.
- MI + RR (Type: EXPERIMENTAL): In this intervention, participants receive both the skills based rate reduction intervention and the more motivationally based MI intervention. This condition will receive Nicotine Replacement Therapy in the form of gum.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic urticaria \[rash (erythema, wheal) for more than 1 month without any known cause\]~* Out-patient~Exclusion Criteria:~* Stimulation-induced urticaria \[physical urticaria (e.g. cold, solar, and heat urticaria), cholinergic urticaria, contact urticaria)\]~* Hypersensitivity to antihistamines or ingredients of a study drug

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desloratadine 5 mg (Type: EXPERIMENTAL): Participants receive desloratadine 5 mg, as one 5-mg tablet and one placebo tablet, orally, once daily in the evening for 2 weeks
- Desloratadine 10 mg (Type: EXPERIMENTAL): Participants receive desloratadine 10 mg, as two 5-mg tablets, orally, once daily in the evening for 2 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive placebo, as two tablets, orally, once daily in the evening for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quality Improvement of Patient-Provider Communication For Colorectal Cancer Screening

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Provider Eligibility:~* Primary care providers (MD, Certified Registered Nurse Practitioner (CRNP), or PA) at the study sites who see patients in the primary care setting at least 1 day per week and had no involvement in the design of the study are eligible for enrollment in the study.~Patient Eligibility:~* Primary care patients who are not up-to-date with colorectal cancer screening are the targeted population for study enrollment.~* Up-to-date with colorectal cancer screening is defined as having completed one of the following:~  * fecal occult blood testing within the past year~ * sigmoidoscopy within the past 5 years~ * colonoscopy within the past 10 years~ * barium enema within the past 5 years.~* Other patient eligibility criteria are:~  * Primary Care Provider (PCP) enrolled in the study~ * clinic visit scheduled with the enrolled PCP during the recruitment period~ * English speaking~ * no prior history of colorectal cancer or adenomatous polyps~ * no prior history of inflammatory bowel disease~Exclusion Criteria:~* Patients who are deemed clinically not appropriate for colorectal cancer screening due to severe comorbidity and/or limited life expectancy as determined by the patient's primary care provider will be excluded from the study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Communication sheet
- Control (Type: OTHER): Standard of care brochures

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of neuroblastoma by histopathology OR bone marrow metastases and high urine catecholamine levels~* Disease must meet risk-related treatment guidelines and any of the following International Neuroblastoma Staging System stages:~  * Stage 4 with (any age) OR without (\> 18 months of age of age) MYCN amplification~ * MYCN-amplified other than stage 1~* No evidence of disease (i.e., in complete response/remission or very good partial response/remission) OR disease resistant to standard therapy (i.e., incomplete response in bone marrow)~* No progressive disease or MIBG-avid soft tissue tumor~PATIENT CHARACTERISTICS:~* No existing renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity ≥ grade 3~* No human anti-mouse antibody (HAMA) titer greater than 1,000 Elisa units/mL~* No history of allergy to mouse proteins~* No active life-threatening infection~* Not pregnant~* Negative pregnancy test~PRIOR CONCURRENT THERAPY:~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients have refractory bone marrow disease (Type: EXPERIMENTAL): This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
- patients have no evidence of disease (Type: EXPERIMENTAL): This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* local advanced or metastatic non-small cell lung cancer~* large cell lung carcinoma or adenocinoma~* Previously treated by TKI-Chemotherapy or Chemotherapy-TKI~* EGFR T790M positive~* No uncontrolled hypertension~* No active bleeding or thrombosis in recent 6 months~* No previously treated with VEGF antibody~Exclusion Criteria:~* newly diagnosed thrombosis~* anti-coagulation therapy~* uncontrolled hypertension~* uncontrolled nephropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Docetaxel, bevacizumab (Type: ACTIVE_COMPARATOR): docetaxel, 75mg/m2, intravenous infusion on day 1. VEGF monoclonal antibody bevacizumab, 7.5 mg/m2, intravenous infusion on day 1, every 21days a cycle，until disease progression, intolerable toxicities, or patient death.
- EGFR TKI (Type: EXPERIMENTAL): osimertinib 80mg oral once daily，until disease progression, intolerable toxicities, or patient death.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Aged 18-75 years inclusive, with documented previously diagnosed type 2 diabetes mellitus (per American Diabetes Association \[ADA\] criteria)~* Residual albuminuria despite stable treatment with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) for at least 8 weeks prior to screening (Albumin:creatinine ratio \[ACR\] of 100 to 3000 mg/g creatinine, inclusive)~* Estimated glomerular filtration rate based on serum creatinine (eGFR, determined by Modification of Diet in Renal Disease \[MDRD\] equation) of ≥ 25 mL/min/1.73 m(2)~* Must be on a stable dose of an ACE inhibitor or ARB for at least 8 weeks prior to screening, but subjects must not be on both an ACE inhibitor and an ARB~* Hemoglobin A1c (HbA1c) \> 6.0% but not \> 10.0% and fasting plasma glucose less than 270 mg/dL at screening~Key Exclusion Criteria:~* Type 1 diabetes mellitus or history of diabetic ketoacidosis~* Previous renal transplant or known non-diabetic renal disease, except related to hypertension~* Undergone renal dialysis at any time in the past~* Received chronic (more than 7 days continuously) systemic glucocorticoid or other immunosuppressive treatment within 8 weeks of screening~* Use of bardoxolone, atrasentan or other endothelin antagonist within 8 weeks of screening~* Received chronic (more than 7 days continuously) non-steroidal anti-inflammatory drug (NSAID) treatment within 2 weeks of screening~* Cardiac failure (class III or IV), history of unstable angina, symptomatic coronary artery disease, myocardial infarction or stroke within 12 weeks of screening~* Poorly-controlled blood pressure (systolic blood pressure \>155 or diastolic blood pressure \>95, with blood pressure measured in the seated position after at least 5 minutes of rest)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Group A) (Type: PLACEBO_COMPARATOR): None
- CCX140-B (Group B) (Type: EXPERIMENTAL): None
- CCX140-B (Group C) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children should be infected with a minimum of 150 eggs/gram of any of the three species of STH (i.e. Ascaris or hookworms or Trichuris).~Exclusion Criteria:~* Not willing to participate~* Unable to give samples for follow up~* Severe intercurrent medical condition~* Diarrhoea at first sampling

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Albendazole (Type: EXPERIMENTAL): Treatment with albendazole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Difference Between Inhalation Anesthesia and Total Intravenous Anesthesia in Free Flap Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Patients who need head and neck cancer excision and free flap reconstruction surgery~Exclusion criteria:~1. preoperative cognitive dysfunction, NYHA CHF \> III or LVEF \< 30%~2. preoperative documented obstructive or restrictive lung disease~3. liver cirrhosis; severe chronic renal insufficiency (GFR \< 30 ml·min-1·1.73 m-2.)~4. peripheral arterial occlusive disease expected to be a contraindication for PiCCO catheter insertion~5. Active cardiac arrhythmias that were assumed to preclude valid assessment using arterial pulse contour analysis~6. anticipated bilateral femoral arterial and central venous catheterization when the jugular and subclavian veins were not available due to surgical extent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TIVA with Propofol in free flap surgery (Type: EXPERIMENTAL): Total intravenous anesthesia(TIVA) with Propofol
- Sevoflurane in free flap surgery (Type: ACTIVE_COMPARATOR): Inhalation anesthesia with Sevoflurane

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, between 18 and 75 years of age, inclusive~* Histologically confirmed NASH diagnosis~Exclusion Criteria:~* Clinically significant acute or chronic liver disease~* Prior liver transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 - Placebo (Type: PLACEBO_COMPARATOR): Cohort 1 - Placebo
- Cohort 1 - NGM282 3mg (Type: EXPERIMENTAL): Cohort 1 - NGM282 3mg
- Cohort 1 - NGM282 6mg (Type: EXPERIMENTAL): Cohort 1 - NGM282 6mg
- Cohort 2 - NGM282 0.3mg (Type: EXPERIMENTAL): Cohort 2 - NGM282 0.3mg
- Cohort 2 - NGM282 1mg (Type: PLACEBO_COMPARATOR): Cohort 2 - NGM282 1mg
- Cohort 2 - NGM282 3mg (Type: EXPERIMENTAL): Cohort 2 - NGM282 3mg
- Cohort 3 - NGM282 1mg (Type: EXPERIMENTAL): Cohort 3 - NGM282 1mg
- Cohort 4 - Placebo (Type: PLACEBO_COMPARATOR): Cohort 4 - Placebo
- Cohort 4 - NGM282 1mg (Type: EXPERIMENTAL): Cohort 4 - NGM282 1mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Cancer patients who are scheduled to receive radiotherapy within the next 3 weeks~  * Total dose at least 2,000 cGy delivered in at least 15 fractions~ * 1 fraction per day, 5 days per week~ * Treatment field to include an area of at least 80 cm2 in the anterior/posterior direction encompassing the upper abdomen~* At risk of developing radiation-induced emesis~* No emesis (retching and/or vomiting) or nausea with severity greater than 2 within the past week~PATIENT CHARACTERISTICS:~Age:~* 16 and over~Performance status:~* ECOG 0-3~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* No jaundice~* No moderate to severe hepatic dysfunction~Renal:~* Not specified~Gastrointestinal:~* No active peptic ulcer~* No lactose intolerance~Other:~* No concurrent condition or illness that contraindicates corticosteroids, serotonin antagonists, or prochlorperazine (e.g., diabetes mellitus)~* No prior unusual or allergic reaction to a serotonin antagonist (ondansetron, dolasetron, or granisetron), corticosteroid, or prochlorperazine~* No condition that would preclude accessibility to treatment or follow-up~* Able and willing to complete diary and quality of life questionnaires in either English or French~* Able to swallow~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* At least 1 week since prior cytotoxic therapy~* No concurrent cytotoxic therapy~Endocrine therapy:~* No concurrent corticosteroids other than topical or inhaled preparations~Radiotherapy:~* See Disease Characteristics~* At least 1 week since prior radiotherapy~* No concurrent cranial radiotherapy~Surgery:~* Not specified~Other:~* At least 2 days since prior medication with antiemetic intent

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extended (6-Week) Varenicline Preloading: Does it Facilitate Smoking Reduction and Cessation?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women aged ≥18 years~* Currently smoking 10 cigarettes per day or more~* Having smoked 5 py or more~* Presenting a CO level in expired air ≥ 10 ppm~* Personally motivated to reduce or stop smoking and indicating a willingness to follow through with protocol requirements~* Willing to sign a statement of informed consent~Exclusion Criteria:~* Myocardial infarction within the last 3 months~* Unstable angina~* Severe cardiac arrhythmia~* Pregnancy or breast feeding~* Use of any form of smokeless tobacco or nicotine substitution~* Having followed any smoking cessation programme during the last 3 months~* Alcohol or other drug addiction~* Use of any form of smokeless tobacco or nicotine substitution~* Participation in any clinical trial within the past 3 months~* Women in childbearing age not willing to use contraception until week 12 after QD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- group A (Type: EXPERIMENTAL): Subjects in Group A will receive varenicline for six weeks .During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
- group B (Type: ACTIVE_COMPARATOR): group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete